US2307189A - X-ray contrast composition - Google Patents

X-ray contrast composition Download PDF

Info

Publication number
US2307189A
US2307189A US321914A US32191440A US2307189A US 2307189 A US2307189 A US 2307189A US 321914 A US321914 A US 321914A US 32191440 A US32191440 A US 32191440A US 2307189 A US2307189 A US 2307189A
Authority
US
United States
Prior art keywords
tetraiodophenolphthalein
sodium
solution
ray contrast
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US321914A
Inventor
Bell William
Jules R Gilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US321914A priority Critical patent/US2307189A/en
Application granted granted Critical
Publication of US2307189A publication Critical patent/US2307189A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461Dispersions, colloids, emulsions or suspensions

Definitions

  • the present invention relates to diagnostic and therapeutic preparations and it particularly relates to improved preparations for use in cholecystographic examinations or in gall bladder radiography.
  • tetraiodophenolphthalein compound when ingested, be fully disintegrated and absorbed in the digestive tract without being converted into sticky and insoluble masses or without being passed through the stomach or digestive tract in unchanged condition.
  • protective colloids such as gelatin
  • organic acids such as citric acid
  • the resultant product which is prepared should be a true solution as contrasted to a colloidal suspension, should have an excess of alkalinity and should be devoid of free acid.
  • the flavoring such as the oil of lemon or saccharin, may be omitted.
  • the caustic soda is added to alkalinize the mixture.
  • the mixture is then stirred and heated to C. and is permitted to stand overnight.
  • the oil of lemon and saccharin may be added at this point or they may be replaced by other suitable flavoring materials.
  • the pH should vary between 7.5 to 10 and preferably between 8 and 9, and although casein, gelatin or agar-agar may be added, desirably these materials are omitted.
  • This method of preparation is much preferable to one in which gelatin and di-sodium tetraiodophenolphthalein are added to water heated to 400, followed by the addition of caustic and citric acid, with or without the addition of coloring matter, oil of lemon and saccharin.
  • citric acid it may preferably be added in the form of the tri-sodium citrate so that it will remain in this condition and most desirably no acid is added to convert either the tetraiodophenolphthalein to the mono-sodium salt or to decrease the amount of sodium in the tri-sodium citrate.
  • salts which may be used are sodium phosphate, particularly dior tri-sodium phosphate, sodium borate or sodium carbonate.
  • the present procedure may also be utilized in the preparation of stable solutions of the disodium salt of tetraiodophenolphthalein in ampule form for intravenous injection, in lieu of making fresh solutions just prior to injection. Where used for intravenous injection the solution is devoid of flavoring materials.
  • the di-sodium salt of tetralodophenolphthalsin is most readily commercialized as a powder which is used to prepare a fresh solution for oil or intravenous administration, the concentration depending upon the dosage and varying from 2 to 7 grams per dose in a suitable amount of water.
  • the substantially alkaline solution of di-sodium salt of tetraiodophenolphthalein is much superior to the substantially neutral solution 0! the di-sodium salt of tetraiodophenolphthalein or the dispersion of the mono-sodium salt of tetraiodophenolphthalein in that the solution 0! the present invention is definitely stable, whereas the last-mentioned solutions will sediment upon standing and result in unsalable products.
  • a stable shadow producing composition for cholecystographic purposes consisting of di-sodium tetraiodophenolphthalein dissolved in a caustic soda solution having a pH of about 8 2.
  • a process of producing a stable sodium tetraiodophenolphthalein solution which comprises alkalinizing a solution of the di-alkali metal salt of tetraiodophenolphthalein with caustic soda to a pH 01' about 8 to 9.

Description

Patented Jan. 5. 1943 X-RAY CONTRAST COMPOSITION William Bell, kly and Jules R. Gilbert, New York, N. Y.
No Drawing. Application March 2, 1940, Serial No. 321,914
2 Claims. (Cl. 16795) The present invention relates to diagnostic and therapeutic preparations and it particularly relates to improved preparations for use in cholecystographic examinations or in gall bladder radiography.
It has been found that certain alkali metal salts of tetraiodophenolphthalein are most useful in connection with cholecystographic examinations or gall bladder radiography, but considerable difiiculty has been experienced in obtaining preparations which will remain stable over along period of time in solution form and will give satisfactory shadows of the gall bladder.
It has been found that these tetraiodophenolphthalein preparations, particularly in the form of the mono-sodium salts, are not stable in water insoluble or emulsion form even with stabilizing agents, such as' gelatin, acacia, tragacanth and so forth.
It is important that the tetraiodophenolphthalein compound, when ingested, be fully disintegrated and absorbed in the digestive tract without being converted into sticky and insoluble masses or without being passed through the stomach or digestive tract in unchanged condition.
It has not been found satisfactory to prepare preparations of these tetraiodophenolphthalein metal salts dispersed in insoluble form with protective colloids or organic acids, although in some instances these may be included. It has been found most satisfactory to prepare true solutions of tetraiodophenolphthalein rather than colloidal dispersions thereof, with a slight or excess alkalinity.
In preparing a preferred compound according to the present invention, it has been found most satisfactory to use the tetraiodophenolphthalein di-sodium salt dissolved in a relatively large amount of water in the presence of an alkali, preferably caustic alkali, such as caustic soda, together with the addition of small amounts of essential oils and saccharin.
Although protective colloids, such as gelatin, may be added or organic acids, such as citric acid, may be included, generally it is preferred to omit these materials.
The resultant product which is prepared, should be a true solution as contrasted to a colloidal suspension, should have an excess of alkalinity and should be devoid of free acid.
To give one preferred formula for making up the composition of the present application, the following materials may be used:
The flavoring, such as the oil of lemon or saccharin, may be omitted.
In making up the above preparation, it has been found most satisfactory to heat the 1600 cc. of water to about 40 and then add the sodium compound with agitation.
Then the caustic soda is added to alkalinize the mixture. The mixture is then stirred and heated to C. and is permitted to stand overnight.
If flavoring is desired, the oil of lemon and saccharin may be added at this point or they may be replaced by other suitable flavoring materials.
Finally the mixture is made up to 2200 cc. by addition of water and then is filtered.
It is found that the resultant preparation when utilized is devoid of colloidally suspended material, will be most satisfactorily absorbed to give the proper shadow or cholecystographic effects and will be devoid of sediment and stable over long periods of time. The pH should vary between 7.5 to 10 and preferably between 8 and 9, and although casein, gelatin or agar-agar may be added, desirably these materials are omitted.
This method of preparation is much preferable to one in which gelatin and di-sodium tetraiodophenolphthalein are added to water heated to 400, followed by the addition of caustic and citric acid, with or without the addition of coloring matter, oil of lemon and saccharin.
Where citric acid is added, it may preferably be added in the form of the tri-sodium citrate so that it will remain in this condition and most desirably no acid is added to convert either the tetraiodophenolphthalein to the mono-sodium salt or to decrease the amount of sodium in the tri-sodium citrate.
It has been found that by preparing the solu- -tion of tetraiodophenolphthalein in the above manner, the solution is buffered and such buflering action may be enhanced by the addition of salts of strong alkalies and weak acids to give a pH of about 8.
Among the salts which may be used are sodium phosphate, particularly dior tri-sodium phosphate, sodium borate or sodium carbonate.
The present procedure may also be utilized in the preparation of stable solutions of the disodium salt of tetraiodophenolphthalein in ampule form for intravenous injection, in lieu of making fresh solutions just prior to injection. Where used for intravenous injection the solution is devoid of flavoring materials.
The di-sodium salt of tetralodophenolphthalsin is most readily commercialized as a powder which is used to prepare a fresh solution for oil or intravenous administration, the concentration depending upon the dosage and varying from 2 to 7 grams per dose in a suitable amount of water.
The substantially alkaline solution of di-sodium salt of tetraiodophenolphthalein is much superior to the substantially neutral solution 0! the di-sodium salt of tetraiodophenolphthalein or the dispersion of the mono-sodium salt of tetraiodophenolphthalein in that the solution 0! the present invention is definitely stable, whereas the last-mentioned solutions will sediment upon standing and result in unsalable products.
As many changes could be made in the features and details, and many apparently widely dlflerent embodiments of this invention could be made without departing from the scope thereof, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.
What is claimed is:
l. A stable shadow producing composition for cholecystographic purposes consisting of di-sodium tetraiodophenolphthalein dissolved in a caustic soda solution having a pH of about 8 2. A process of producing a stable sodium tetraiodophenolphthalein solution, which comprises alkalinizing a solution of the di-alkali metal salt of tetraiodophenolphthalein with caustic soda to a pH 01' about 8 to 9.
WILLIAM BELL. JULES R. GILBERT.
US321914A 1940-03-02 1940-03-02 X-ray contrast composition Expired - Lifetime US2307189A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US321914A US2307189A (en) 1940-03-02 1940-03-02 X-ray contrast composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US321914A US2307189A (en) 1940-03-02 1940-03-02 X-ray contrast composition

Publications (1)

Publication Number Publication Date
US2307189A true US2307189A (en) 1943-01-05

Family

ID=23252597

Family Applications (1)

Application Number Title Priority Date Filing Date
US321914A Expired - Lifetime US2307189A (en) 1940-03-02 1940-03-02 X-ray contrast composition

Country Status (1)

Country Link
US (1) US2307189A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419657A (en) * 1964-06-23 1968-12-31 Dagra Nv Iodopanoic acid in a hydrogel
US4101647A (en) * 1975-02-05 1978-07-18 Schering Aktiengesellschaft Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419657A (en) * 1964-06-23 1968-12-31 Dagra Nv Iodopanoic acid in a hydrogel
US4101647A (en) * 1975-02-05 1978-07-18 Schering Aktiengesellschaft Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof

Similar Documents

Publication Publication Date Title
US2820740A (en) Therapeutic preparations of iron
US2773068A (en) Substitution derivatives of imidazoline alkanoic quaternary ammonium hydroxide and process of preparing same
US2659690A (en) Effervescent barium sulfate-pectin x-ray contrast composition
US2132662A (en) Aliphatic amine salts of cevitamic acid
US2307189A (en) X-ray contrast composition
US2230616A (en) Bismuth nicotinate
US2294888A (en) Pheonthiazine suspension
IL39005A (en) Salts of iodomethanesulphonic acid with pentahydroxyhexylamine and n-alkyl derivatives thereof
DE938502C (en) Method of making a colloidal iron preparation
US2429899A (en) Aluminum salts of bile acids
US3413340A (en) N-(carboxymethyl)-3-alkoxy-polyiodoanilide compounds
US2684323A (en) Procaine ascorbate preparation
US1841694A (en) Therapeutic iodine solution
US1741761A (en) Quinine compound and process of making the same
DE2321498A1 (en) 3- SQUARE BRACKET ON 4- (3-HYDROXY2,4,6-TRIJODPHENOXY) -PHENYL SQUARE BRACKET TO -ALANINE, METHOD OF ITS MANUFACTURING AND ITS USE AS AN X-RAY CONTRAST AGENT
US2132351A (en) Stable aqueous solutions of subtances having an anesthetic effect
US1650333A (en) Process of converting medicaments, antiseptic agents and cauterization means into a stable and readily dosable form
Beilensohn et al. An Investigation of the Value of Lead Compounds in the Treatment of Malignant Tumours: Members of the Liverpool Medical Research Organization Director, M. Datnow, MD, FRCSE
US2635102A (en) Boron derivatives of ascorbic acid
US3855405A (en) Radiographic contrast composition containing 2{40 ,6{40 -diiodo-dl-thyronine and methods of use thereof
DE676050C (en) Process for the preparation of 3-oxy-4-carbaminobenzene-1-arsic acid
US2049662A (en) Vanadium compounds of nu-methylene sulphonic acids of diamino dihydroxy arsenobenzene and sodium salts thereof
USRE17281E (en) Abyl-azo-diaminosyridines ttseftll as bactericides and process of making
US2038586A (en) Composition for treatment of mia and method of preparing same
GB1391843A (en) X-ray contrast agents